Related Experiment Video

Updated: Jul 15, 2026

Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test
06:35

Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test

Published on: April 27, 2016

[Endothelial dysfunction in patients with chronic heart failure, and possibilities of its correction with

L I Ol'binskaia, Zh M Sizova, N G Kolbaia

    Klinicheskaia Meditsina
    |April 11, 2007
    PubMed

    Insights

    Isosorbide-5-mononitrate monocinque improved endothelial function and reduced angina in chronic heart failure patients. This treatment normalized vasodilation and improved heart function with manageable side effects.

    Area of Science:

    • Cardiology
    • Vascular Biology
    • Pharmacology

    Background:

    • Vascular endothelial dysfunction is a key factor in chronic heart failure (CHF) progression.
    • Patients with CHF complicating coronary artery disease (CAD) often exhibit impaired endothelium-dependent vasodilation.

    Purpose of the Study:

    • To investigate the effect of isosorbide-5-mononitrate monocinque on endothelial function in patients with NYHA II class CHF and CAD.
    • To assess the antianginal activity and impact on cardiac parameters of monocinque therapy.

    Main Methods:

    • The study involved patients with CHF complicating CAD and stable exertional angina.
    • Endothelial function was assessed using reactive hyperthermia tests measuring brachial artery vasodilating response.
    • Patients received 40 mg daily dose of monocinque for 12 weeks.

    Main Results:

    • Monocinque treatment normalized endothelium-dependent vasodilation, increasing brachial artery response from 8.2% to 11.1%.
    • Significant antianginal activity was observed in 85.7% of patients, with a 59.3% reduction in anginal attacks.
    • Ejection fraction improved by 8.7%, indicating enhanced morphofunctional cardiac parameters.

    Conclusions:

    • Isosorbide-5-mononitrate monocinque effectively improves endothelial function in CHF patients with CAD.
    • Monocinque demonstrates significant antianginal efficacy and improves cardiac function.
    • The therapy is generally well-tolerated, with expected nitrate-related side effects in a minority of patients.

    Related Concept Videos

    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Heart Failure II: Pathophysiology01:29

    Heart Failure II: Pathophysiology

    Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
    Heart Failure Drugs: Inotropic Agents01:26

    Heart Failure Drugs: Inotropic Agents

    Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
    Heart Failure Drugs: Diuretics01:22

    Heart Failure Drugs: Diuretics

    Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.